Company Profile
Saniona AB (publ), a clinical-stage biopharmaceutical company focuses on discovering, developing, and delivering innovative treatments for neurological and psychiatric disorders in Ireland, the United States, Germany, Denmark, and the United Kingdom.
It also develops medicines modulating ion channels. The company's product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity.
Its portfolio also includes Tesomet, an oral investigational therapy that has completed Phase 2 clinical trial for the treatment of hypothalamic obesity and Prader-Willi syndrome, ACP-711, a positive allosteric modulator of GABAA a3 containing receptors that has completed Phase 1 clinical trial for the treatment of essential tremor, SAN903, a novel medicine based on inhibition of the calcium-activated potassium ion channel, which has completed preclinical development for the treatment of inflammatory bowel disease, SAN2219, a subtype selective positive allosteric modulator of GABAA a2- a3- and a5 that is in preclinical stage for treatment of acute repetitive seizures, SAN2355 to treat resistant focal onset seizures, SAN2668, a therapy for severe pediatric epilepsies, including developmental epileptic encephalopathies, and SAN2465, a negative allosteric modulator to treat major depressive disorder.
It has research and collaboration agreements with Boehringer Ingelheim International GmbH to research, develop, manufacture, and commercialize therapeutics. Its portfolio also includes license agreement with Productos Medix, S.A. de C.V. develop and commercialize tesofensine and/or Tesomet, research services agreement and a collaboration agreement with Cephagenix ApS to identify and develop novel migraine treatments, and research collaboration with AstronauTx to research, develop, manufacture, and commercialize therapeutics for Alzheimer's disease. Founded in 2011, the company is headquartered in Glostrup, Denmark.